ArticleAnnals of surgical oncology2026
Optimal Time Between Completion of Preoperative Chemotherapy and Surgery for Locally Advanced Pancreatic Cancer.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- ASO Author Reflections: What is the Role of Time Interval Between Preoperative Chemotherapy and Surgery in Locally Advanced Pancreatic Cancer?Annals of surgical oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMultimodal treatment with preoperative chemotherapy is increasingly used for locally advanced pancreatic cancer (LAPC) to enable surgical resection. However, the optimal time between the last cycle of preoperative chemotherapy and surgery remains unclear. This study aimed to evaluate the association between timing of surgery after preoperative chemotherapy and overall survival of patients with LAPC.
methodsPatients with LAPC who underwent pancreatic resection after preoperative chemotherapy between 2018 and 2023 were enrolled from a prospectively maintained database. The cohort was stratified by a predefined interval between the last cycle of chemotherapy and surgery (short interval: < 4 weeks vs long interval: ≥ 4 weeks).
resultsAfter preoperative chemotherapy, 169 patients underwent surgery, including 56 (33.1%) patients in the short-interval group and 113 (66.9%) patients in the long-interval group. Baseline characteristics, surgical procedures, and postoperative morbidity were comparable between the two groups. Most patients received FOLFIRINOX (85.5 %) with a median of nine cycles. Patients with the long interval showed significantly improved overall survival from the time of LAPC diagnosis (20.7 vs 29.5 months; p = 0.019) as well as from surgery (16.1 vs 23.1 months; p = 0.024). In multivariable analysis, the interval of 4 weeks or longer was an independent predictor of improved survival. Further analysis suggested an optimal time window of 4-8 weeks between the last chemotherapy cycle and surgery.
conclusionAn interval of at least 4 weeks between the last cycle of preoperative chemotherapy and surgery for LAPC was associated with significantly improved overall survival, with an optimal window of 4-8 weeks.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.